ArticleMicromachines2023
Reduced Graphene Oxide as a Platform for the Immobilization of Amino-Cyclodextrins.
Article in Micromachines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 7 citations in OpenAlex.
- Chitosan/Montmorillonite/Graphene Oxide Composites for the Adsorption of Dyes from Single-Component Solutions, Binary Mixtures, and Real Textile Wastewaters: On Understanding the Adsorption Interactions.Langmuir : the ACS journal of surfaces and colloids · 2025Article
- Facile Synthesis of Platinum Nanoparticle-Embedded Reduced Graphene Oxide for the Detection of Carbendazim.Materials (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
In the present work, we reported on a method to combine amino β-cyclodextrins (CD1) with reduced graphene oxide (obtained by the electrochemical reduction of graphene oxide, erGO) to produce a glassy carbon electrode (GCE) modified with both CD1 and erGO (CD1-erGO/GCE). This procedure avoids the use of organic solvents such as hydrazine or long reaction times and high temperatures. The material combining both CD1 and erGO (CD1-erGO/GCE) was characterized by SEM, ATR-FTIR, Raman, XPS, and electrochemical techniques. As proof-of-concept, the determination of the pesticide carbendazim was carried out. The spectroscopic measurements, especially XPS, proved that CD1 was covalently attached to the surface of the erGO/GCE electrode. The attachment of cyclodextrin at the reduced graphene oxide produced an increase in the electrochemical behavior of the electrode. The cyclodextrin-functionalized reduced graphene oxide, CD1-erGO/GCE, showed a larger sensitivity (1.01 μA/μM) and a lower limit of detection for carbendazim (LOD = 0.50 μM) compared with the non-functionalized material, erGO/GCE, (sensitivity = 0.63 μA/μM and LOD = 4.32 μM, respectively). Overall, the results of the present work show that this simple method is suitable to attach cyclodextrins to graphene oxide, maintaining their inclusion abilities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.